Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma

NCT02633059 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02633059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
December 30, 2015
Completion date
November 1, 2022
Enrollment
33 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

loss of chromosome 17p, recurrent plasma cell myeloma